Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00315757 · ClinicalTrials.gov registry record · Phase 2
Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 2 study, sponsored by Human Genome Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT00315757 is a Phase 2 study that has completed, run by Human Genome Sciences. The registered enrollment target is 105 participants.
The verdict
NCT00315757, a Phase 2 study, has completed, sponsored by Human Genome Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with bortezomib and bortezomib alone in subjects with relapsed or refractory multiple myeloma (MM).
Interventions
- DRUG Bortezomib
- BIOLOGICAL Mapatumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2006-05 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00315757
The ClinicalTrials.gov registry entry for NCT00315757 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Human Genome Sciences, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bortezomib is the first listed.
NCT00315757 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00315757 about?
NCT00315757 is a clinical study titled "Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with bortezomib and bortezomib alone in subjects with relapsed or refractory multiple myeloma (MM).
What is the current status of trial NCT00315757?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2006-05. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00315757?
The interventions under investigation include: Bortezomib (DRUG), Mapatumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00315757?
This trial is sponsored by Human Genome Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.